“Plinabulin has proven to be a promising asset for both NSCLC treatment and Neutropenia prevention, and as such, partnering with pharmaceutical companies has become an integral part of our overall clinical development strategy,” sai...
epidemiology, and bioethics to inform evidence- and science-based product decisions that put people first. The OCMO also chairs the Pharmaceutical Development Committee, which reviews product development plans to ensure that our products address unmet needs and benefit the people who will ultimately use...
Life sciences-focused search firm Slone Partners placed Mike Spigarelli as chief medical officer of Lumen Bioscience in Seattle, WA. “As an extremely skilled industry leader with three decades of medical, pharmaceutical and academic experience, Mike Spigarelli has a thorough understanding of clinical a...
clinical-stage global biopharmaceutical company, and also serves on an expert panel for the Reagan Foundation for the FDA, developing recommendations for the FDA related to an evidence generation strategy for the United States. She is a faculty affiliate of the Division of Medical Ethics, Department...
9.Represent the Company and its programs to external audiences, including the investment, medical and regulatory communities, as well as pharmaceutical or biotechnology industry collaborators/partners Qualifications: Education/Experience: The ideal candidate will offer: ...
Eck began his professional career at the University of Pennsylvania where he was Director of the gene therapy programme, after this he has held a number of leaderships roles in oncology drug and biomarker development at prominent pharmaceutical companies. ...
“Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced that Joe Hulihan, MD, has been appointed Chief Medical Officer. Dr. Hulihan will succeed outgoing CMO,...
("IBD"), today announced the appointment ofSheldon Sloan, M.D., M. Bioethics, as Chief Medical Officer.Dr. Sloanbrings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation ...
Health and Pharmaceutical PRINCETON, N.J.--(BUSINESS WIRE)--Adare Pharmaceuticals, Inc. announced that Dr. Peter Richardson has joined the Company as Vice President, Research & Development and Chief Medical Officer. Dr. Richardson will be responsible for leading our Research and Development efforts...
Kevin has almost 30 years of experience in R&D in the pharmaceutical industry. He has experience in multiple national, regional and global clinical roles, building organizations across Clinical Development and Medical Affairs previously at Novartis and Celgene. At Celgene, he was Vice President leading...